Merck
CN

Y0000821

吗多明

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价

别名:
N-(Ethoxycarbonyl)-3-(4-morpholino)sydnone imine, SIN-10
经验公式(希尔记法):
C9H14N4O4
CAS号:
分子量:
242.23
MDL编号:
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

molsidomine

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

格式

neat

SMILES字符串

CCOC(=O)N=C1O[N-][N+](=C1)N2CCOCC2

InChI

1S/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3/b10-8-

InChI key

XLFWDASMENKTKL-NTMALXAHSA-N

正在寻找类似产品? Visit 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Molsidomine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Exclamation mark

警示用语:

Warning

危险声明

预防措施声明

危险分类

Acute Tox. 4 Oral

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

为方便起见,与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码?

在网站页面上,产品编号会附带包装尺寸/数量一起显示(例如:T1503-25G)。请确保 在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503
货号
-
25G
包装规格/数量

其它示例:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题?欢迎随时联系我们技术服务 寻求帮助

批号可以在产品标签上"批“ (Lot或Batch)字后面找到。

Aldrich 产品

  • 如果您查询到的批号为 TO09019TO 等,请输入去除前两位字母的批号:09019TO。

  • 如果您查询到的批号含有填充代码(例如05427ES-021),请输入去除填充代码-021的批号:05427ES。

  • 如果您查询到的批号含有填充代码(例如 STBB0728K9),请输入去除填充代码K9的批号:STBB0728。

未找到您寻找的产品?

部分情况下,可能未在线提供COA。如果搜索不到COA,可在线索取。

索取COA

J L Wautier
Presse medicale (Paris, France : 1983), 17(20), 1037-1040 (1988-05-25)
Platelet suppressive agents have been shown to improve the prognosis of coronary diseases such as myocardial infarction and unstable angina. Several markers of platelet activation during myocardial ischemia have been found to be increased. Platelet granule constituents (beta thromboglobulin or
[Nitric oxide in therapy of angina pectoris: nitrates or molsidomine?].
V Schächinger et al.
Der Internist, 38(5), 438-447 (1997-05-01)
Effects of molsidomine and other NO-containing vasodilators on cyclic GMP formation.
E Böhme et al.
European heart journal, 4 Suppl C, 19-24 (1983-05-01)
E Singlas et al.
Annales de cardiologie et d'angeiologie, 32(8), 503-509 (1983-12-01)
Molsidomine is well absorbed by the gastro-intestinal tract and is taken up by the liver during the first passage. Its bioavailability is 60 per cent. Digestive or sublingual absorption is rapid: maximal plasma concentrations are obtained 0.5 to 1.0 hours
Cardiovascular pharmacology of molsidomine.
O Thulesius
Bibliotheca cardiologica, (38)(38), 234-243 (1984-01-01)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门